Paeds · clinical-pharmacology-and-therapeutics
Corticosteroid therapy and adverse effects
Also known as Glucocorticoid therapy in children · Prednisolone dosing and weaning · Adrenal suppression from steroids · Stress-dose hydrocortisone · Corticosteroid adverse effects
A fellowship approach to corticosteroid therapy in children covering glucocorticoid versus mineralocorticoid potency and the equivalent-dose ladder (hydrocortisone, prednisolone, methylprednisolone, dexamethasone), weight-based prednisolone and dexamethasone dosing for asthma and croup, the hypothalamic-pituitary-adrenal axis and how exogenous steroids suppress it, the recognition and emergency management of adrenal crisis with age-banded stress-dose hydrocortisone, the safe weaning of longer courses, and the full spectrum of adverse effects from growth suppression to osteopenia.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child on long-term or high-dose corticosteroids who collapses, vomits, or becomes hypoglycaemic during a febrile illness is in adrenal crisis until proven otherwise
- Abrupt cessation of systemic corticosteroids after more than two to three weeks of pharmacologic dosing without a weaning plan
- Failure to give stress-dose hydrocortisone before surgery, sepsis, or major trauma in a child with known or suspected adrenal suppression
- Inhaled corticosteroid escalated to a very high dose (especially fluticasone) without checking for declining growth, weight, or cortisol
- Interpreting a single random cortisol as reassuring during critical illness, when the axis is dynamically stressed
- Using dexamethasone where mineralocorticoid activity is needed, or hydrocortisone where profound anti-inflammatory potency is needed, without understanding potency equivalence
Life stages
Care settings
Clinical exam formats
Board mappings
- General and Community Paediatrics
- Current 2026 PREP curriculum — Learning Objective: Safe prescribing and medication management in infants, children and young people
- Current 2026 PREP curriculum — Learning Objective 2.2.1: Recognise, prioritise and manage an acutely ill infant, child or young person
- Renewed curriculum for first-year trainees from 2027 — Learning goal 6: Clinical management – essential general paediatrics
- Renewed curriculum for first-year trainees from 2027 — Learning goal 9: Quality and safety, including medication safety
- Clinical Applications
- Medical Sciences
- Long Cases
- Short Cases
- 4. Professional skills and knowledge: Patient management
- 7. Patient safety, including safe prescribing
- 8. Quality improvement and patient safety
- General Paediatrics: Prescribes and monitors medicines safely, including corticosteroids and adrenal replacement therapy
- Foundation of Practice (FOP)
- Theory and Science (TAS)
- Applied Knowledge in Practice (AKP)
- Clinical
- History
- Communication
- General Pediatrics Content Outline — Domain 10: Principles of Pharmacology and Medication Management
- General Pediatrics Content Outline — Domain 4: Endocrine Disorders
- General Pediatrics Content Outline — Universal Task 4: Management and Treatment
- Systems-Based Practice 2: Medication Safety and Stewardship
- Patient Safety/Quality Improvement 1: Medication Safety
- Medical Knowledge 2: Diagnostic and Therapeutic Decision Making
- Medical Expert
- Pharmacist
- Pediatrics: Core EPA #5 — Recommending and Initiating Pharmacologic Interventions
Overview & Definition
Picture a five-year-old gasping with an asthma exacerbation who improves within hours of a single dose of oral prednisolone, a toddler with croup whose stridor melts after dexamethasone, and a teenager on long-term prednisolone for nephrotic syndrome who arrives in the emergency department collapsed and hypoglycaemic with a fever. These three children sit on the two edges of the same medicine: its capacity to switch off inflammation, and its capacity to switch off the adrenal cortex. Corticosteroid therapy is the prescribing discipline that uses the first while defending against the second. [11] [7]
A corticosteroid earns its place when inflammation, immune activation, or hormone deficiency is the disease. Three properties decide which agent you reach for. Glucocorticoid potency measures anti-inflammatory strength relative to hydrocortisone. Mineralocorticoid activity measures the tendency to retain sodium and water and waste potassium. Duration of action measures how long the drug suppresses the hypothalamic-pituitary-adrenal (HPA) axis after a single dose — short-acting agents allow the axis to recover between doses, long-acting agents suppress it continuously. Hydrocortisone is the physiological replacement; prednisolone is the workhorse anti-inflammatory; dexamethasone is the high-potency, minimal-mineralocorticoid option. Choosing well means matching the property to the job. [7] [8]
References12ShowHide
- [1]Paniagua N, Lopez R, Muñoz N, et al. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. The Journal of pediatrics, 2017.PMID 29173304
- [2]Elkharwili DA, Ibrahim OM, Elazab GA, Elrifaey SM Two regimens of dexamethasone versus prednisolone for acute exacerbations in asthmatic Egyptian children. European journal of hospital pharmacy, 2020.PMID 32419935
- [3]Cetinkaya F, Tüfekçi BS, Kutluk G A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. International journal of pediatric otorhinolaryngology, 2004.PMID 15013613
- [4]Watterberg KL, Walsh MC, Li L, Chawla S, et al. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. The New England journal of medicine, 2022.PMID 35320643
- [5]Patel L, Wales JK, Kibirige MS, Massarano AA, et al. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Archives of disease in childhood, 2001.PMID 11567945
- [6]Schwartz RH, Neacsu O, Ascher DP, Alpan O Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clinical pediatrics, 2012.PMID 23043135
- [7]Husebye ES, Pearce SH, Krone NP, et al. Adrenal insufficiency. Lancet, 2021.PMID 33484633
- [8]Hahner S, Ross RJ, Arlt W, Bancos I, et al. Adrenal insufficiency. Nature reviews. Disease primers, 2021.PMID 33707469
- [9]Nowotny H, Ahmed SF, Bensing S, Beun JG, et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine, 2021.PMID 33661460
- [10]Woodcock T, Barker P, Daniel S, Fletcher S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency. Anaesthesia, 2020.PMID 32017012
- [11]Auron M, Raissouni N Adrenal insufficiency. Pediatrics in review, 2015.PMID 25733761
- [12]Lee SC, Baranowski ES, Sakremath R, Saraff V, et al. Hypoglycaemia in adrenal insufficiency. Frontiers in endocrinology, 2023.PMID 38053731